Table 2.
Clinical development of immunocytokines/fusion proteins against solid tumors.
| Immunocytokine | Malignancy | Combination | Phase | Registry |
|---|---|---|---|---|
| Hu14.18-IL2 | Neuroblastoma/GD2+ Tumors | Monotherapy | I | NCT00003750 |
| Hu14.18-IL2 | Relapsed/refractory neuroblastoma | Ex vivo expanded NK Cells | I | NCT03209869 |
| Hu14.18-IL2 | Recurrent neuroblastoma | Sargramostim and Isotretinoin | II | NCT01334515 |
| Hu14.18-IL2 | Melanoma | Monotherapy | II | NCT00109863 |
| Hu14.18-IL2 | Residual/refractory neuroblastoma | Monotherapy | II | NCT00082758 |
| L19-TNFα | Stage III/IV limb melanoma | Melphalan | I | NCT01213732 |
| L19-TNFα | Advanced solid tumors | Doxorubicin | I | NCT02076620 |
| L19-TNFα | Solid tumors, colorectal cancer | Monotherapy | I/II | NCT01253837 |
| L19-TNFα | Unresectable or metastatic soft tissue sarcoma | Doxorubicin | I | NCT03420014 |
| F16-IL2 | Solid tumors | Doxorubicin | I/II | NCT01131364 |
| F16-IL2 | Solid tumor, breast cancer, melanoma, NSCLC | Paclitaxel | I/II | NCT01134250 |
| L19-IL2 | Advanced solid tumors, RCC | Monotherapy | I/II | NCT01058538 |
| L19-IL2 | Oligometastatic solid tumor | SABR | I | NCT02086721 |
| L19-IL2 | Metastatic melanoma | Dacarbazine | I/II | NCT02076646 |
| L19-IL2 | Advanced/metastatic pancreatic cancer | Gemcitabine | I | NCT01198522 |
| NHS-IL2LT | Metastatic or locally advanced solid tumors | Cyclophosphamide | I | NCT01032681 |
| NHS-IL2LT | NSCLC | Local Tumor Irradiation | I | NCT00879866 |
| NHS-IL12 | Epithelial/malignant mesenchymal tumors | Monotherapy | I | NCT01417546 |
| NHS-IL12 | Advanced solid tumors | Avelumab | I | NCT02994953 |
| CEA-IL2v (RO6895882) |
Advanced/metastatic solid tumors | Monotherapy | I | NCT02004106 |
| CEA-IL2v (RO6895882) |
Locally advanced/metastatic solid tumors | Atezolizumab | I | NCT02350673 |
| FAP-IL2v (RO6874281) |
Solid tumors, breast cancer, head and neck cancer | Trastuzumab Cetuximab |
I | NCT02627274 |
| FAP-IL2v (RO6874281) |
Advanced and metastatic solid tumors. | Atezolizumab Gemcitabine Vinorelbine |
II | NCT03386721 |
| huKS-IL-2 (EMD273066) |
Refractory epithelial carcinoma | Monotherapy | I | NCT00016237 |
| huKS-IL-2 (EMD273066) |
Ovarian, prostate, colorectal, NSCLC | Cyclophosphamide | I | NCT00132522 |
| BC1-IL12 (AS1409) |
Metastatic malignant melanoma, RCC | Monotherapy | I | NCT00625768 |
| LAG3-Ig (IMP321) | NSCLC head and neck cancer |
Pembrolizumab | II | NCT03625323 |
| VEGF-Ig (HB002.1T) | Solid tumors | Monotherapy | I | NCT03636750 |
| PAP-GM-CSF (APC8015) | Prostate cancer | Bevacizumab | II | NCT00027599 |